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MicroRNAs (miRNAs) are a class of non-coding RNAs that post-transcriptionally silence target mRNAs. Dysregulation
of miRNAs is a frequent event in several diseases, including cancer. One miRNA that has gained special interest in
the field of cancer research is miRNA-125b (miR-125b). MiR-125b is a ubiquitously expressed miRNA that is aberrantly
expressed in a great variety of tumors. In some tumor types, e.g. colon cancer and hematopoietic tumors, miR-125b is
upregulated and displays oncogenic potential, as it induces cell growth and proliferation, while blocking the apoptotic
machinery. In contrast, in other tumor entities, e.g. mammary tumors and hepatocellular carcinoma, miR-125b is heavily
downregulated. This downregulation is accompanied by de-repression of cellular proliferation and anti-apoptotic
programs, contributing to malignant transformation. The reasons for these opposing roles are poorly understood.
We summarize the current knowledge of miR-125b and its relevant targets in different tumor types and offer several
hypotheses for the opposing roles of miR-125b: miR-125b targets multiple mRNAs, which have diverse functions in
individual tissues. These target mRNAs are tissue and tumor specifically expressed, suggesting that misregulation by
miR-125b depends on the levels of target gene expression. Moreover, we provide several examples that miR-125b
upregulation dictates oncogenic characteristics, while downregulation of miR-125b corresponds to the loss of tumor
suppressive functions. Thus, in different tumor entities increased or decreased miR-125b expression may contribute
to carcinogenesis.
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The discovery of microRNAs (miRNAs) twenty years
ago [1] revealed a new layer of post-transcriptional regu-
lation of gene expression in all areas of cell biology.
MiRNAs play a crucial role in epigenetic gene regulation
and have been linked to development and differentiation,
cell growth and cell death [2-5]. They are misregulated
in several disorders, including neurodegenerative dis-
eases, cardio-vascular diseases and cancer [2-5]. MiR-
NAs are small, non-coding single stranded RNAs, 21-25
nucleotides in length that are generated from a primary
miRNA transcript (pri-miRNA). Often several miRNAs
are clustered on one pri-miRNA transcript [6]. A nu-
clear ribonuclease termed Drosha excises 70-100 nucleo-
tide hairpins, termed precursor miRNAs (pre-miRNAs).
Upon nuclear export, a second ribonuclease known as* Correspondence: julia.banzhaf@dzne.lmu.de
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this article, unless otherwise stated.Dicer cleaves the pre-miRNAs, giving rise to a miRNA
duplex. Upon binding to the RNA-Induced Silencing
Complex (RISC) the passenger strand is cleaved and re-
leased. The mature miRNA associated with RISC can
bind to complementary mRNAs, leading to either trans-
lational repression or mRNA degradation, depending on
the level of complementarity between the miRNA and
the target sequence. Typically, one miRNA has multiple
target mRNAs and, thus, can regulate several genes or
even pathways in parallel (reviewed in [7]).
The development of novel techniques to overexpress
miRNAs on the one hand, and to sequester endogenous
miRNAs via “sponges” [8], “tough decoys” [9] or “antag-
omirs” [10] on the other hand, led to the understanding
of fundamental roles of miRNAs in physiological pro-
cesses as well as disease mechanisms, including cancer.
Systematic miRNA profiling of human cancer samples
and corresponding normal tissue, led to the identifica-
tion of multiple aberrantly deregulated miRNAs in can-
cer. So-called miRNA signatures of miRNA expressionnsee BioMed Central Ltd. This is an Open Access article distributed under the
icense (http://creativecommons.org/licenses/by/2.0), which permits unrestricted
ium, provided the original work is properly credited. The Creative Commons
ivecommons.org/publicdomain/zero/1.0/) applies to the data made available in
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diagnostic tool that allows for predictions of clinical out-
come (reviewed in [11]).
MiRNA 125b in cancer
One miRNA that has gained special interest in the field
of cancer research is miRNA 125b (miR-125b), which is
misregulated in a broad variety of tumors [12]. However,
while miR-125b upregulation in some tumor entities sug-
gests oncogenic potential of miR-125b, downregulation in
other tumor types suggests that miR-125b is rather tumor
suppressive.
MiR-125b is the human orthologue of lin-4, one of the
very first miRNAs identified in C. elegans [1,13]. Studying
lin-4 in C. elegans revealed the fundamental mechanisms
of miRNA signaling and regulation. Lin-4 is essential for
post-embryonic proliferation and differentiation in the
worm (for further reading see excellent reviews [14,15]).
Human miR-125b is a ubiquitously expressed miRNA
with highest expression levels in brain and ovaries,
followed by the thyroid gland, pituitary gland, epididy-
mis, spleen, testes, prostate, uterus, placenta and liver (see
www.microRNA.org). MiR-125b belongs to the miR-125
family, consisting of miR-125a, miR-125b-1 and miR-
125b-2 which result in almost identical products of dis-
tinct genes. Although mature miR-125a and miR-125b
have different sequences, they share the same seed region
(nucleotides 1-9), suggesting that they regulate the same
target mRNAs. MiR-125a has been shown to be downreg-
ulated in colorectal cancer, breast cancer, gastric cancer,
non-small cell lung cancer (NSCLC) and glioblastomas,
the causes and consequences of which are discussed else-
where [12].
Mature miR-125b is generated from two genes, miR-
125b-1 (on chromosome 11q24) and miR-125b-2 (on
chromosome 21q21). It has been demonstrated that both
loci are within so-called fragile sites which are com-
monly deleted in breast, lung, ovary and cervical cancer
[16], implying a miR-125b loss of function in those
tumor types. Many other miRNA profiling studies re-
vealed that miR-125b is also downregulated in head and
neck tumors [17], gliomas [18], melanomas [19], endo-
metrial tumors [20], oral squamous cell carcinomas [21],
osteosarcomas and Ewing sarcomas [22]. However, the
molecular mechanisms that lead to miR-125b downregu-
lation in these cancer types are not fully understood. In
some cases hypermethylation in the promoter regions of
miR-125b has been shown to block miR-125b expression
levels in cancer [23,24].
Several other tumor entities, however, show enhanced
miR-125b signaling. In colorectal cancer, miR-125b up-
regulation is associated with poor prognosis. Further-
more, miR-125b has been shown to be upregulated in
certain leukemias [25-27], gastric and follicular cancers[28,29], pancreatic cancer [30] and some brain tumor de-
rived glioma cell lines [31,32]. The reasons for a dramatic
upregulation of miR-125b in these tumor types are not very
well understood. Copy number variations and chromosomal
translocations occur frequently at miRNA loci leading to
aberrant miRNA expression [33]. In myelodysplastic syn-
drome, which may progress to acute myeloid leukemia, a
t (2;11) (p21; q23) translocation leads to a 6- to 90-fold upreg-
ulation of miR-125b-1 and -2 without affecting the expres-
sion of other genes located close to that region [34]. Further,
in B-cell acute lymphoblastic leukemia the insertion of miR-
125b-1 into a immunoglobulin heavy chain locus has been
identified in one patient [35]. For other tumor types the
causes for miR-125b upregulation are unknown so far.
Numerous studies have proven a role for miR-125b in
proliferation, apoptosis and cellular differentiation [36,37],
already suggesting a potentially important role during car-
cinogenesis. Recent studies demonstrated that miR-125b
directly targets the tumor suppressor gene p53 [32,38],
which is essential to maintain genome stability and plays a
central role in regulation of apoptosis (reviewed in [39]).
This direct interaction has been demonstrated for human
and zebrafish p53, however there is no conserved miR-
125b seed region in the mouse p53 3’UTR. Yet, it has been
demonstrated that miR-125b interacts with multiple
mRNAs, including apoptosis regulators, such as Bak1 and
Puma as well as cell cycle reglators, such as cyclin C and
cdc25c that belong to the p53 network in human, zebra-
fish and mouse [37]. Thus, by inhibiting key players of the
p53 network across several species, miR-125b interferes
with multiple cancer relevant pathways.
Other oncogenic signaling molecules that are relevant
for tumorigenesis have been described to be directly tar-
geted by miR-125b. The verified target genes v-erb-b 2
and 3 avian erythroblastic leukemia viral oncogene homo-
log (ERBB2/3), also named human epidermal growth fac-
tor receptor (Her) 2 and 3 [40] are heavily upregulated in
many invasive mammary carcinomas [41]. ERBB2/3 has
also been linked to ovarian, bladder, stomach, salivary and
lung carcinomas [42]. Increased ERBB2/3 alters multiple
signaling pathways, including kinase signaling, and, thus,
impairs normal cellular control mechanisms, giving rise to
malignant tumor cell transformation [42]. This implies
that the reduction of miR-125b may play a significant role
in the development of these tumors [42].
In the following paragraphs, the oncogenic and tumor
suppressive potential of miR-125b in the different tumor
entities is summarized, with special focus on signaling
cascades targeted by miR-125b and their implications in
tumor formation.
The oncogenic potential of miR-125b
In several tumor types elevated miR-125b levels have been
detected. MiR-125b appears to downregulate anti-apoptotic
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cellular proliferation, thereby promoting tumor growth
(see Figure 1 and Table 1). The following miR-125b targets
have been identified in different cancers:
Hematopoietic tumors
Chromosomal translocations cause a severe upregulation
of up to 90-fold of miR-125b in myelodysplastic syndrome
(MDS), acute myeloid leukemia (AML) and B-cell acute
lymphoid leukemia (B-ALL). In these cases, miR-125b
overexpression is the only consistent abnormality found,
suggesting that it is the main oncogenic event [34,35,45].
One study very elegantly demonstrated that miR-125bFigure 1 “The bad guy”: miR-125b associated with oncogenic signalin
and androgen signaling have been shown to cause an upregulation of miR
promote the formation of the indicated tumor types. See also Table 1. *Up
controversially discussed, see main text.overexpression is indeed the sole oncogenic event re-
quired for the development of leukemias: Bousquet et al.
generated retroviral vectors to overexpress miR-125b and
transplanted mice with fetal liver cells that were infected
with the virus. 16 weeks post transplantation the animals
showed a significant increase in white blood count associ-
ated with macrocytic anemia, suggesting pro-proliferative
properties of miR-125b. Half of the mice transplanted with
miR-125b overexpressing fetal liver cells succumbed to
hematopoietic malignancies with different phenotypes,
including malignant B-ALL, T-cell AML or myelopro-
liferative neoplasms within 12 to 29 weeks post trans-
plantation [25]. The authors additionally showed thatg in cancer. t (2;11) (p21, q23) translocations, miR-125b-1 insertions
-125b. This blocks the translation of target mRNAs which might
regulation of miR-125b in brain tumors and prostate cancer is
Table 1 miR-125b associated with oncogenic signaling in cancer
Tumor type Direction of misregulation miR-125b targets Comments Ref.
Hematopoetic tumors Up BCL2 Regulator of apoptosis [26]
Up CBFβ Counteracts myeloid cell differentiation [27]
Up Trp53inp1 Regulator of apoptosis [43]
Up NA NA [25]
Colon cancer Up in colon cancer with poor prognosis p53 Prognostic indicator for colorectal cancer [38]
Non-small-cell lung
cancer (NSCLC)
Up in serum from patients with poor prognosis NA Prognostic serum marker for NSCLC [44]
Follicular cancer Up NA NA [29]
Gastric tumors Up NA Pro-proliferative, anti-apoptotic [28]
Pancreatic cancer Up NA NA [30]
NA: not analyzed.
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that potentiates the effect of other oncogenes in vivo, such
as BCR-ABL-induced leukemia [25]. Two additional stud-
ies confirmed the oncogenic potential of miR-125b in the
hematopoietic system [43,46]: Overexpression of miR-
125b in hematopoietic stem cells caused a dose-dependent
myeloproliferative disorder that progressed to lethal mye-
loid leukemia in mice [46]. Further, transgenic mice mim-
icking the t (11;14) (q24; q32) translocation found in
human B-cell precursor acute lymphoblastic leukemia that
causes overexpression of miR-125b, developed lethal B-
cell malignancies with clonal proliferation [43]. Subse-
quent in vitro experiments identified B-cell lymphoma-2
(BCL2), core-binding factor subunit β (CBFβ) and trans-
formation related protein 53 inducible nuclear protein 1
(Trp53inp1) as direct miR-125b targets in myeloid cells,
thereby counteracting pro-apoptotic pathways and mye-
loid cell differentiation [26,27,43].
Colon cancer
MiR-125b also plays a crucial role in colorectal cancer.
High levels of miR-125b expression in colorectal tumors
are associated with reduced survival rates, most likely by
directly targeting the p53 network and its downstream
signaling molecules, such as p21, and thereby reducing
pro-apoptotic stimuli [38].
Non-small-cell lung cancer (NSCLC)
A study by Yuxia et al. demonstrated that miR-125b levels
are elevated in serum of NSCLC patients by 10-fold [44].
It has recently been demonstrated that miRNAs are se-
creted within exosomes and may act on other cells taking
up the exosomes. Transiting miRNAs can be detected in
body fluids and may serve as a biomarker for NSCLC and
other diseases [47]. Indeed, increasing miR-125b levels in
serum are correlated to more malignant NSCLC stages as
well as poor survival [44]. A second study confirmed the
correlation of miR-125b serum levels and poor survival
rates as well as poor response to cis-platin chemotherapy,suggesting that serum levels of miR-125b might be a use-
ful prognostic and therapeutic marker for NSCLC [48].
No such correlation has been found for miR-125b expres-
sion in primary tumor tissue so far.
Others
In follicular cancers, gastric tumors and pancreatic can-
cer miR-125b expression has been found to be increased.
In gastric tumors miR-125b displays oncogenic, pro-
proliferative characteristics [28-30].
The tumor suppressive potential of microRNA 125b
Tumor suppressive potential of miR-125b has been de-
scribed for multiple tumor types, in which miR-125b
levels are decreased. Next to inhibition of cell growth and
pro-apoptotic stimuli, miR-125b targets numerous pro-
teins that alter kinase signaling, cellular migration and in-
vasion as well as angiogenesis (see Figure 2 and Table 2).
Bladder cancer
MiR-125b is significantly downregulated in bladder can-
cer tissue by about 50% as well as in bladder cancer cell
lines [49-51]. Overexpression of this miRNA in bladder
cancer cell lines suppresses the potential to form colonies
and to develop tumors in nude mice [49-51]. mRNA
expression of the cell cycle transition molecule E2F tran-
scription factor 3 (E2F3) is inversely correlated to miR-
125b expression in cancerous tissues and cell lines,
implying a miR-125b dependent regulation of E2F3 [49].
Cell invasion and migration is also regulated by miR-125b
in bladder cancer cell lines. Matrix metalloproteinase 13
(MMP13) most likely mediates this effect, which has been
demonstrated to be directly targeted by miR-125b [50].
Breast cancer
MiR-125b is heavily downregulated in malignant breast
tumors [24,40,52]. Reduced expression levels of miR-125b
are most likely due to enhanced DNA methylation in the
promoter regions, as demonstrated in breast cancer cell
Figure 2 “The good guy”: miR-125b associated with tumor suppressive signaling in cancer. MiR-125b deletions, DNA hypermethylation
and androgen signaling have been described to reduce miR-125b expression. This in turn causes the upregulation of multiple target mRNAs
which might promote the formation of the indicated tumor types. Only the best characterized miR-125b target mRNAs are listed. For a complete
list, see Tables 2 and 3. *Downregulation of miR-125b in gliomas and prostate cancer is controversially discussed, see main text.
Banzhaf-Strathmann and Edbauer Cell Communication and Signaling 2014, 12:30 Page 5 of 13
http://www.biosignaling.com/content/12/1/30lines as well as mammary carcinoma tissue [24]. Further,
deletions of the miR-125b loci have been described for
human breast cancer tissues [16]. Computational ap-
proaches were used to identify potential miR-125b targets.
Two of the first miR-125b targets that were identified and
verified are ERBB 2 and 3 [40]. Activating ERBB2/3 ex-
pression and signaling by miR-125b downregulation in-
duces cellular proliferation via the Ras-mitogen activated
protein kinase (MAPK) signaling pathway and inhibits
programmed cell death via the mammalian target of rapa-
mycin (mTOR) pathway. Strikingly, these effects are moreprominent in transformed breast cancer cell lines com-
pared to non-transformed human mammary epithelial
cells [40]. Further, downregulation of miR-125b in meta-
static breast cancer induces the expression of erythropoi-
etin (EPO) and its receptor EPOR also via the ERBB2/
Her2 pathway, promoting cellular survival [52]. Also, miR-
125b downregulation induces the expression of the proto-
oncogene v-ets avian erythroblastosis virus E26 oncogene
homolog 1 (ETS1), involved in cell cycle transition, cell
growth and proliferation. Interestingly, ETS1 is overex-
pressed in invasive breast cancer samples [24]. Glutamyl
Table 2 miR-125b associated with tumor suppressive signaling in cancer
Tumor entity Direction of
deregulation
miR-125b targets Comments Ref.
Bladder cancer Down E2F3 Regulator of colony formation, cell division [49]
Down MMP13 Regulator of cell migration and invasion [50]
Down NA NA [51]
Breast cancer Down EPO, EPOR Regulator of differentiation and survival of erythroid cells [52]
Down ETS1 Regulator of cell proliferation, clonogenicity and cell cycle progression [24]
Down ENPEP, CK2-α, CCNJ, MEGF9 Cell proliferation and anchorage-independent growth [53]
Down ERBB2/ERBB3 Regulator of migration and invasion [40]
Down MUC1 Regulator of proliferation and apoptosis induction [54]
Endometrial
cancer
Down ERBB2 Regulator of cell invasion [20]
Ewing sarcoma Down IGF1, IGFR, mTOR, RSK1 Growth inhibitory properties [55]
Down PI3K/Akt/mTOR Regulator of proliferation, migration and invasion [56]
Head and neck
tumors
Down TACSTD2 (TROP2) Causes mitogen-activated protein kinase pathway dysfunction [17]
Hepatocellular
carcinoma (HCC)
Down Bcl-W, Mcl-1, IL-6R Regulator of apoptosis [57,58]
Down BCL2 Regulator of apoptosis [59]
Down PIGF Regulator of invasion/angiogenesis [60]
Down LIN28B Regulator of cell migration and invasion [61]





Down NA Regulator of proliferation [21]
Osteosarcoma Down STAT3 Regulator of proliferation and migration [22]
Ovarian cancer Down BCL3 Regulator of proliferation and clonal formation [63]
Down HER2/HER3 Regulator of proliferation and angiogenesis [64]
Skin cancer Down c-Jun Regulator of proliferation [19]
Thyroid cancer Down NA NA [29]
NA: not analyzed.
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(CK2-α), cyclin J (CCNJ), and multiple epidermal growth
factor-like-domains 9 (MEGF9) are additional miR-125b
targets that are upregulated in human breast cancer sam-
ples and may contribute to tumor progression [53].
Endometrial cancer
One study showed that miR-125b is downregulated by
approximately 30% in endometrioid endometrial cancer
[20]. Downregulation of miR-125b in human endometrial
cancer cell lines increased cell invasiveness which could be
rescued by miR-125b overexpression. This effect is most
likely mediated by the miR-125b target ERBB2 [20].
Ewing sarcoma
In this pediatric malignancy, a proto-oncogenic fusion
protein named EWS/Fli1 inhibits expression of a groupof miRNAs, including miR-125b [55]. Interestingly, miR-
125b has many predicted targets in the IGF-signaling
pathway which is a key driver of Ewing carcinogenesis.
One of these targets is ribosomal protein S6 kinase A1
(RSK1) which is directly downregulated by miR-125b in
Ewing sarcoma cell lines, resulting in reduced cell
growth and proliferation [55]. A second study identified
the PI3K/Akt/mTOR pathway to be regulated by miR-
125b in Ewing sarcoma cell lines, confirming its tumor
suppressive potential [56].
Head and neck tumors
In head and neck squamous cell carcinoma, DNA hyper-
methylation in the promoter region of miR-125b reduces
the expression of this miRNA by about 100-fold [17].
Tumor-associated calcium signal transducer 2 (TACSTD2),
a cell-surface glycoprotein, has been reported to be
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as miR-125b target in head and neck cancer. Disinhibition
of TACSTD2 aberrantly induces MAPK signaling promot-
ing tumor growth and proliferation [17].
Hepatocellular carcinoma
Several studies have identified reduced miR-125b expres-
sion in liver cancer [57]. Multiple miR-125b targets were
found to be upregulated in hepatocellular carcinoma, in-
cluding BCL2, BCL2 like 2 (Bcl-W), myeloid cell leukemia
sequence 1 (Mcl-1), interleukin-6 receptor (IL6R), lin-28
homolog B (LIN28B) and placenta growth factor (PIGF).
This in turn inhibits the induction of apoptosis, promotes
tumor angiogenesis, cell migration and invasion of cell
lines and, thus, promotes carcinogenesis [57-62]. Strik-
ingly, higher expression of miR-125b in hepatocellular car-
cinoma correlates with better survival rates, most likely
by reducing Akt phosphorylation levels and subsequent
inhibitory effects on cell growth and proliferation [62].
This further confirms the tumor suppressive nature of
miR-125b in this tumor entity.
Osteosarcoma
In osteosarcomas, miR-125b is reduced about 2.3-fold
compared to adjacent non-cancerous tissue [22]. Accord-
ingly, overexpression of miR-125b suppresses human
osteosarcoma cell proliferation and migration in vitro as
well as tumor growth in nude mice [22]. The signal trans-
ducer and activator of transcription 3 (STAT3) is dir-
ectly targeted by miR-125b in osteosarcoma cell lines
and, interestingly, alters the expression of miR-125b in a
regulatory feedback loop, suggesting that tightly controlled
levels of STAT3 are crucial for normal tissue homeo-
stasis [22].
Ovarian cancer
Ovarian cancer shows reduced miR-125b levels by ap-
proximately 75% compared to normal tissue [63,64].
Thus, overexpression of miR-125b in ovarian cancer cell
lines does not only induce cell cycle arrest and inhibit
proliferation, but also reduces tumor growth in a xeno-
graft model [63]. These growth inhibitory effects of miR-
125b are mediated by the miR-125b target B-cell CLL/
lymphoma 3 (BCL3). Next to BCL3, ERBB2/3 (Her2/Her3)
are also downregulated upon miR-125b overexpression in
human ovarian cancer cell lines, further demonstrating
that this pathway is involved in the development of mul-
tiple tumor types in which miR-125b is tumor suppressive.
ERBB2/3 regulates angiogenesis in the chicken chorioallan-
toic membrane assay via the Akt/p70S6K1/HIF-1α/VEGF
pathway [64]. Strikingly, ERBB2/3 has been shown to be
upregulated in ovarian cancer tissues, suggesting enhanced
angiogenenesis upon miR-125b downregulation in this
tumor entity [64].Skin cancer
The expression of miR-125b is significantly reduced in
malignant melanoma cell lines and tissue samples com-
pared to melanocytes [19]. Forced expression of miR-125b
suppresses proliferation and migration in melanocytes,
confirming a tumor suppressive function of miR-125b.
Overexpression of miR-125b is accompanied by reduced
c-Jun protein expression in melanoma cells. C-Jun con-
trols a wide set of substrates that are relevant for cell
cycle, proliferation and differentiation [19], implying that
miR-125b deregulation promotes c-Jun signaling and,
therefore, carcinogenesis in malignant melanoma.
Dual role of miR-125b
While in the above listed tumor types, miR-125b has a
distinct oncogenic or tumor suppressive function, the role
of miR-125b is controversially discussed in several other
tumor entities. In those tumor types, miR-125b expression
is elevated in tumor tissue compared to normal tissue and
miR-125b targets that suggest oncogenic potential have
been identified. However, other studies describe a down-
regulation of miR-125b and identify pathways that are reg-
ulated by miR-125b which rather imply tumor suppressive
functions in those tumors (see Table 3).
Brain tumors
MiR-125b is most abundantly expressed in the brain,
where it is involved in neurogenesis and neural develop-
ment by repressing multiple targets [71]. Given its pro-
proliferative nature, two studies analyzed the effects of
miR-125b overexpression in human glioma cell lines [31,65].
By targeting Connexin 43, an astrocytic gap junction pro-
tein that is commonly downregulated in astrocytomas
[72], and Bmf (Bcl-modifying factor), miR-125b protects
glioma cells from apoptosis in vitro and promotes human
glioma cell proliferation. These findings were confirmed
in vivo, in which transplanted miR-125b overexpressing
glioma cell lines displayed enhanced cell growth and
tumor size [65]. However, the current literature controver-
sially discusses whether miR-125b is solely oncogenic
in brain tumors: two studies describe a rather tumor sup-
pressive function of miR-125b in brain derived cells
[18,66]. Smits et al. show that miR-125b is critical for the
regulation of glioma stem cell proliferation as it directly
targets the cell cycle regulators cyclin dependent kinase 6
(CDK6) and cell division cycle 25 homolog A (CDC25A).
MiR-125b expression is low in CD133-positive stem cells,
leading to the upregulation of these two cell cycle regula-
tors promoting growth and proliferation [66]. In line with
these findings, another study demonstrates that miR-125b
is downregulated in glioblastoma-associated endothelial
cells, resulting in increased expression of its target, myc-
associated zinc finger protein (MAZ), a transcription
factor that regulates vascular endothelial growth factor
Table 3 miR-125b associated with oncogenic and tumor suppressive signaling in cancer
Tumor type Direction of misregulation miR-125b targets Comments Ref.
Brain tumors Up in ATRA differentiated glioblastoma cell lines Bmf Regulator of apoptosis [31]
Up Connexin43 Anti-apoptotic, pro-proliferative [65]
Up in neuroblastoma cells p53 Regulator of apoptosis [32]
Down MAZ Regulator of angiogenesis [18]
Down in glioma stem cells CDK6 and CDC25A Regulator of stem cell proliferation [66]
Prostate cancer Up in androgen-independent prostate cancer Bak1 Pro-proliferative [67]
Up p14ARF Pro-proliferative, anti-apoptotic [68]
Down in androgen-treated prostate cancer cells IGF1R Anti-proliferative [69]
Down NA Translational control [70]
NA: not analyzed.
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MAZ protein expression is also elevated, leading to en-
hanced VEGF signaling that supposedly shuts down miR-
125b expression in a feedback loop [18], suggesting that
miR-125b acts as a tumor suppressor.
While the oncogenic potential of miR-125b was ana-
lyzed in glioma cell lines, the tumor suppressive function
of miR-125b was investigated in glioma stem cells and
glioblastoma-associated endothelial cells. The usage of dif-
ferent cell types may account for the opposite results and
future analyses of human glioma tissues will be needed to
elucidate under which conditions miR-125b acts rather
oncogenic or tumor suppressive in brain tumors.
Prostate cancer
The role of miR-125b in prostate cancer is also contro-
versially discussed. Several studies report an upregula-
tion of miR-125b in malignant prostate cancer cell lines
as well as clinical tissues of prostate cancer [67,70]. Shi
et al. report that miR-125b expression is induced by an-
drogen signaling, as androgens can bind to the promoter
region of miR-125b. This in turn downregulates the
anti-apoptotic proteins BCL2 homologous antagonist/
killer 1 (Bak1) and p14ARF and, thus, promotes prolifera-
tion of androgen independent prostate cancer [67,68].
The upregulation of miR-125b by androgens has been
further demonstrated in a more recent study investigat-
ing androgen-mediated ovarian follicular development,
leading to the repression of pro-apoptotic signaling
events [73]. In contrast, another study describes an in-
hibitory effect of androgen treatment on the expression
of a miRNA cluster, containing miR-125b, in prostate
cancer cell lines [69]. This results in the upregulation
of multiple miR-125b target genes, including insulin-
like growth factor 1 receptor (IGF1R). Accordingly, the
authors conclude that androgen-repression of miR-125b
promotes androgen-dependent growth of prostate cancer
cell lines through the de-repression of IGF1R. Future
studies will be needed to fully elucidate the implicationsof androgen-signaling on miR-125b expression and
the precise role of miR-125b deregulation in prostate
carcinogenesis.
It is important to highlight that most of the studies de-
scribed in the paragraphs above measured miR-125b ex-
pression levels in heterogeneous tissue extracts and not
purified cancer cells. Thus, the up- or downregulation of
miR-125b could be a consequence of changes in cellular
composition of the tumors compared to normal tissue
rather than a specific miR-125b activating or repressing
event. Thus, tissue heterogeneity might account for the
opposing results described for brain tumors and prostate
cancer.
Conclusion
The six classical hallmarks of cancer are escape from
growth suppression, maintenance of proliferation, resist-
ance to cell death, induction of angiogenesis, activation of
invasion and metastasis and replicative immortality [74].
MiR-125b modulates several of these pathways through
multiple target genes, resulting in either oncogenic or
tumor suppressive modes of action, which contribute to
or inhibit carcinogenesis, respectively. Several hypotheses,
why miR-125b exerts oncogenic or tumor suppressive po-
tential, depending on the tissues analyzed, might explain
the opposing roles of miR-125b in different cancers:
Same, same, but different – the same miR-125b targets
can have diverse effects in individual tissues
Multiple target genes have been described for miR-125b,
which have been shown to be more or less relevant in
tumor initiation and progression in different tissue types.
For example, many solid tumors have mutations in the
tumor suppressor gene p53. However, while the vast
majority of colorectal tumors and NSCLC carry p53 mu-
tations (see http://p53.free.fr/index.html), the absolute fre-
quency of p53 mutations in breast cancer is significantly
lower [75]. Consequently, overexpression of miR-125b
that further reduces p53 expression and activity in colon
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ing the apoptotic machinery [76]. Thus, miR-125b acts as
classical oncogene in those tumors. This is further sup-
ported by the finding that miR-125b expression levels are
correlated with reduced survival rates in these entities
[38,44]. In contrast, the observed downregulation of miR-
125b in mammary tumors and other cancer tissues might
actually inhibit tumor growth through increased p53 ex-
pression. However, the increase in expression of other
miR-125b targets, such as the EGF receptor family mem-
bers ERBB2/3 might be overall more relevant in breast
cancer tissue, as overexpression of this gene is one of the
most prominent oncogenic drivers in mammary carcin-
oma. ERBB2/3 has been shown to be overexpressed in
breast, ovarian, bladder, stomach, and salivary carcinomas,
thereby impairing normal cellular control mechanisms and
giving rise to malignant tumor cell transformation [42].
Interestingly, miR-125b is heavily downregulated in several
of these ERBB2/3-driven tumor entities [12], allowing for
further ERBB2/3 upregulation [40,64], thereby promoting
malignant transformation.
Hence, due to tumor specific activation/inactivation of
miR-125b regulated signaling pathways both upregula-
tion and downregulation of miR-125b may promote car-
cinogenesis in different tumors. For example, miR-125b
induction may promote oncogenic pathways in some
tumor types predominantly via the inhibition of the p53
axis, e.g., in the case of colon carcinoma and NSCLC
[31,32,59]. On the contrary, downregulation of miR-125b in
other tumor types induces oncogenic pathways, e.g., ERBB2/
3 signaling in mammary carcinoma [40,41]. This suggests
that the combination of balanced levels of miR-125b as
well the expression of its target genes is crucial for proper
physiological function.
Overexpression or downregulation of miR-125b induces
tissue specific oncogenic or tumor suppressive functions,
respectively
MiR-125b targets both oncogenes and tumor suppressor
genes. As summarized above, the overexpression of miR-
125b in tissues, e.g., the hematopoietic system [34,35,45] or
colorectal tumors [38], is an oncogenic event, as anti-
apoptotic proteins are downregulated. In contrast, down-
regulation of miR-125b is associated with loss of tumor
suppressive modes of action, e.g., in mammary [24,40,52]
or ovary tissue [22], since pro-proliferative proteins
are upregulated. Therefore, one can hypothesize that
miR-125b upregulation dictates oncogenic characteris-
tics, while downregulation of miR-125b corresponds to
the loss of tumor suppressive functions by this miRNA.
This is further supported by the fact that overexpression of
miR-125b has never been correlated to tumor suppressive
functions and that loss of miR-125 has never been shown
to activate tumor suppressive pathways in vivo so far.But what determines upregulation or downregulation
of miR-125b in different tumor types?
Not much is known about the transcriptional regula-
tion of miR-125b. Expression profiles of cancer samples
compared to normal tissue indicate that global miRNA
downregulation is a very common event during carcino-
genesis [77]. The downregulation of miR-125b is observed
in multiple tumors, but the molecular mechanisms have
been elucidated only for a few cancer types so far. It is be-
lieved that genotoxic events repress miR-125b expression
[32]. In mammary, cervical and ovarian tumors, deletions
at fragile sites have been described that cause the deletion
of the miR-125b-1 gene [16], which implies a loss-of-
function mechanism, as reduced miR-125b levels allow for
oncogene activation in those entities. Another mechanism
that shuts down miR-125b expression is DNA hyperme-
thylation that has been described for head and neck tu-
mors and invasive breast cancer [23,24]. Promoter DNA
methylation is known to be a rather specific event during
carcinogenesis, since only selected genes are hypermethy-
lated in a tumor cell [78]. This suggests that tissue specific
silencing of the tumor suppressor miR-125b in head and
neck tumors and breast cancer by DNA methylation con-
fers a selective advantage to the cells that does not occur
in other tumor entities. It is very likely that tissue specific
transcriptional regulators, such as enhancers/repressors
and transcription factors control miR-125b expression
[79] that can have particular consequences: By now it is
very well appreciated that miRNAs function by repressing
target mRNAs that should not be expressed (reviewed in
[77]). Loss of miR-125b expression consequently enables
target gene expression even in the absence of signaling
events. This promotes carcinogenesis, e.g. by ERBB2/3 up-
regulation, irrespective of the molecular mechanisms lead-
ing to miR-125b loss. Further, miRNAs and their targets
are very often co-activated or co-repressed by the same in-
coming signal. This guarantees that unwanted stochastic
signaling events do not cause activation or repression of
target gene expression and that signaling fluctuations are
efficiently buffered (reviewed in [77]). Hence, miRNAs
balance and buffer signaling events, crucial for proper tis-
sue homeostasis. In the case of miR-125b downregulation,
this causes a loss of tumor suppressive control mecha-
nisms leading to aberrant activation of multiple oncogenes
in a tissue specific manner (see above).
The upregulation of miR-125b might regulate different
signaling pathways in varying cell types. For instance,
miR-125b could repress a set of tumor suppressors prom-
inently expressed in one type of cells, thereby serving as
an oncomiR. In a different cell type or when using cancer
cell lines that have different transcriptional programs
with specific oncogenes prominently expressed, miR-125b
overexpression might repress the expression of these on-
cogenes and thereby serve as a tumor suppressor. Hence,
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that has been described for a few tumor entities only.
Mutations, deletions, chromosomal translocations, copy
number variations or any other genetic alteration that
changes expression levels are believed to be stochastic
events in sporadic tumor formation that equip the cell
with tumor initiating/promoting advantages compared to
non-transformed cells [80]. Chromosomal translocations
are a classical hallmark of hematopoietic tumors, and
occur at a much higher frequency than in other malignan-
cies [81]. In MDS, AML and B-ALL, chromosomal trans-
locations at the miR-125b locus cause an almost 100-fold
induction of miR-125b expression, which is the major
oncogenic event in these cases [34,35,45]. This provides
the cells with a growth advantage since anti-apoptotic
pathways are downregulated. Such miR-125b-inducing
translocations have not been described for solid tumor
tissues, most likely because chromosomal translocations
occur much less frequently [81]. As a result, upregulation
of miR-125b expression by chromosomal translocations
is a very rare event that is restricted to hematopoietic
tumors, ultimately leading to tissue specific oncogenic
miR-125b signaling. In contrast, in Ewing sarcoma, a
chromosomal translocation involving a transcription fac-
tor inhibits the expression of the miRNA-cluster in which
miR-125b is located, leading to repression of miR-125b
expression [55]. This in turn de-represses oncogenic sig-
naling leading to tumorigenesis.
MiR-125b is upregulated in a few other tumor types,
such as prostate cancer [67,70]. In prostate cancer, the
induction of miR-125b has been linked to elevated andro-
gen signaling [67], which is a hallmark of prostate carcino-
genesis and promotes androgen-dependent proliferation
in early stage prostate cancer [82]. Androgen-dependent
upregulation of miR-125b is most likely restricted to pros-
tate tissue only. The causes for miR-125b upregulation in
colorectal cancer and brain tumors are unknown. Never-
theless, since miR-125b targets very important tumor sup-
pressor genes, such as the p53 network, overexpression of
miR-125b is a clear oncogenic event that promotes car-
cinogenesis in the tissues in which upregulation occurs.
Limitations and future directions
Current data on the pathomechanism of miR-125b in
carcinogenesis were mostly generated in immortalized
cell lines and were only partially verified in vivo. In some
cases xenograft models were used to demonstrate the
tumor suppressive potential of miR-125b in vivo: it was
shown that miR-125b overexpression inhibits tumor for-
mation by inducing apoptotic pathways using bladder
cancer cell lines [49-51], osteosarcoma cell lines [22] and
ovarian cancer cell lines [63]. It is noteworthy that those
studies generally show that altered miR-125b expression
affects cell growth in vitro and in xenograft modelsrather than measuring de novo tumorigenesis. Only a
few studies clearly demonstrated real oncogenic potential
of miR-125b in vivo: The transplantation of fetal liver cells
and hematopoietic stem cells overexpressing miR-125b,
as well as a transgenic mouse model mimicking the
t (11;14) (q24; q32) translocation induced leukemia in mice
[25,43,46], proving that miR-125b is a classical oncogene
in the hematopoietic system.
Nevertheless, these models represent very valuable
tools to study principle functions of miRNA signaling
and provide further insights into the role of miR-125b tar-
gets in carcinogenesis. However, they do not reflect the
full picture of tumorigenesis as foreign cells with dramat-
ically forced expression of miR-125b (in the leukemia
mouse model, retrovirus induced miR-125b expression
was up to 800-fold above normal levels) were adminis-
tered into immune compromised animals [83]. Therefore,
for the future study of miR-125b function, transgenic
miR-125b animal models will be needed which allow for
specific overexpression/knockdown in individual cell types
and tumor types that reflect better the actual situation in
human cancer patients. Especially miR-125b knockout
models in specific tissue types will be needed to address
the question whether miR-125b truly is a tumor suppres-
sor and absolutely relevant for proper tissue homeostasis.
Such studies will reveal in more detail how aberrant miR-
125b expression, as it is observed in human malignancies,
contributes to the malignant transformation of tumors
in vivo.
In summary, miR-125b is a “double-edged” miRNA
that has multiple targets which control pro-proliferative
and pro-apoptotic signaling pathways in parallel and which
has to be tightly regulated under physiological conditions.
If this level of regulation is lost during carcinogenesis,
oncogenic or tumor suppressive pathways are activated or
blocked. Due to tissue specific signaling cascades, disturb-
ing the miR-125b equilibrium can have opposing effects:
if miR-125b is downregulated, the “good guy” with its
tumor suppressive functions is lost, oncogenic pathways
(e.g., ERBB2/3) are activated and pro-apoptotic cascades
are repressed, resulting in malignant transformation. If the
equilibrium is shifted towards miR-125b overexpression
due to chromosomal translocations or transcriptional acti-
vation, miR-125b transforms into the “bad guy” and pro-
motes oncogenic signaling by for example downregulating
p53 and other apoptosis-inducing pathways.
In the future, the diverse roles of miRNAs in the patho-
genesis of multiple diseases will be further established,
and potential therapeutic strategies to target aberrantly
expressed miRNAs might be successfully developed [84].
For this purpose, the in-depth understanding of miRNA
signaling in different tissue types and diseases will be
essential, in order to fully elucidate the precise func-
tion of individual miRNAs. This will provide the potential
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groups, but to also design individualized miRNA based
novel therapies.
Abbreviations
AML: Acute myeloid leukemia; ATRA: All-trans-retionic acid; Bak1: BCL
homologous antagonist/killer 1; B-ALL: B-cell acute lymphoid leukemia;
BCL2: B-cell lymphoma-2; BCL3: B-cell CLL/lymphoma 3; Bcl-W: BCL2 like 2;
Bmf: Bcl-modifying factor; CK2-α: Casein kinase II subunit α; CBFβ: Core-
binding factor subunit β; CCNJ: Cyclin J; CDC25a: Cell division cycle 25
homolog A; CDK6: Cyclin dependent kinase 6; E2F3: E2F transcription factor
3; ENPEP: glutamyl aminopeptidase; EPO: Erythropoietin; EPOR: Erythropoietin
receptor; ERBB: v-erb-b2 avian erythroblastic leukemia viral oncogene
homolog; ETS1: v-ets avian erythroblastosis virus E26 oncogene homolog 1;
Her: Human epidermal growth factor receptor; HIF-1α: Hypoxia inducing
factor 1 α; IGF1R: Insulin-like growth factor 1 receptor; IL6R: Interleukin-6
feceptor; LIN28B: Lin-28 homolog B.; MAPK: Mitogen activated protein kinase;
MAZ: Myc-associated zinc finger protein; Mcl-1: Myeloid cell leukemia
sequence 1; MDS: Myelodysplatic syndrome; MEGF9: Multiple epidermal
growth factor-like domains 9; miRNA: microRNA; miR-125b: microRNA 125b;
MMP13: Matrix metalloproteinase; mTOR: Mammalian target of rapamycin;
p21: cyclin dependent kinase inhibitor 1; p53: tumor suppressor gene p53;
PIGF: placenta growth factor; Pre-miRNA: Precursor microRNA; Pri-
miRNA: Primary microRNA; Ref: Reference; RISC: RNA-induced silencing
complex; RSK1: Ribosomal protein S6 kinase A1; STAT3: Signal transducer and
activator of transcription 3; TACSTD2: Tumor-associated calcium signal
transducer 2; Trp53inp1: Transformation related protein 53 inducible nuclear
protein 1; VEGF: Vascular endothelial growth factor.
Competing interests
The authors declare that they have no competing interest.
Authors’ contributions
JBS and DE set up the outline of the review. JBS wrote the review with
critical input from DE. Both authors read and approved the final manuscript.
Acknowledgements
We thank Denise Orozco and Stephanie May for critical comments to the
manuscript.
Author details
1German Center for Neurodegenerative Diseases, Site Munich, Schillerstr. 44,
80336 Munich, Germany. 2Adolf Butenandt Institute, Biochemistry,
Ludwig-Maximilians University Munich, Schillerstr. 44, 80336 Munich,
Germany. 3Munich Cluster of Systems Neurology (SyNergy), Munich,
Germany.
Received: 14 February 2014 Accepted: 18 April 2014
Published: 28 April 2014
References
1. Lee RC, Feinbaum RL, Ambros V: The C. elegans heterochronic gene lin-4
encodes small RNAs with antisense complementarity to lin-14. Cell 1993,
75:843–854.
2. Zhao Y, Samal E, Srivastava D: Serum response factor regulates a muscle-
specific microRNA that targets Hand2 during cardiogenesis. Nature 2005,
436:214–220.
3. Yekta S, Shih IH, Bartel DP: MicroRNA-directed cleavage of HOXB8 mRNA.
Science 2004, 304:594–596.
4. Poy MN, Eliasson L, Krutzfeldt J, Kuwajima S, Ma X, Macdonald PE, Pfeffer S,
Tuschl T, Rajewsky N, Rorsman P, Stoffel M: A pancreatic islet-specific
microRNA regulates insulin secretion. Nature 2004, 432:226–230.
5. Abe M, Bonini N: MicroRNAs and neurodegeneration: role and impact.
Trends Cell Biol 2013, 23:30–36.
6. Altuvia Y, Landgraf P, Lithwick G, Elefant N, Pfeffer S, Aravin A, Brownstein
MJ, Tuschl T, Margalit H: Clustering and conservation patterns of human
microRNAs. Nucleic Acids Res 2005, 33:2697–2706.
7. He L, Hannon GJ: MicroRNAs: small RNAs with a big role in gene regulation.
Nat Rev Genet 2004, 5:522–531.
8. Ebert MS, Neilson JR, Sharp PA: MicroRNA sponges: competitive inhibitors
of small RNAs in mammalian cells. Nat Meth 2007, 4:721–726.9. Haraguchi T, Ozaki Y, Iba H: Vectors expressing efficient RNA decoys
achieve the long-term suppression of specific microRNA activity in
mammalian cells. Nucleic Acids Res 2009, 37:e43.
10. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, Stoffel
M: Silencing of microRNAs in vivo with ‘antagomirs’. Nature 2005,
438:685–689.
11. Garzon R, Calin GA, Croce CM: MicroRNAs in Cancer. Annu Rev Med 2009,
60:167–179.
12. Xie B, Ding Q, Han H, Wu D: miRCancer: a microRNA–cancer association
database constructed by text mining on literature. Bioinformatics 2013,
29:638–644.
13. Wightman B, Ha I, Ruvkun G: Posttranscriptional regulation of the
heterochronic gene lin-14 by lin-4 mediates temporal pattern
formation in C. elegans. Cell 1993, 75:855–862.
14. Abbott AL: Uncovering new functions for microRNAs in Caenorhabditis
elegans. Curr Biol 2011, 21:R668–R671.
15. Esquela-Kerscher A: The lin-4 microRNA: The ultimate micromanager.
Cell Cycle 2014, 13:1060–1061.
16. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu
M, Rattan S, Bullrich F, Negrini M, Croce CM: Human microRNA genes are
frequently located at fragile sites and genomic regions involved in
cancers. Proc Natl Acad Sci U S A 2004, 101:2999–3004.
17. Nakanishi H, Taccioli C, Palatini J, Fernandez-Cymering C, Cui R, Kim T, Volinia S,
Croce CM: Loss of miR-125b-1 contributes to head and neck cancer
development by dysregulating TACSTD2 and MAPK pathway. Oncogene
2013, 33:702–712.
18. Smits M, Wurdinger T, van het Hof B, Drexhage JA, Geerts D, Wesseling P,
Noske DP, Vandertop WP, de Vries HE, Reijerkerk A: Myc-associated zinc
finger protein (MAZ) is regulated by miR-125b and mediates VEGF-
induced angiogenesis in glioblastoma. FASEB J 2012, 26:2639–2647.
19. Kappelmann M, Kuphal S, Meister G, Vardimon L, Bosserhoff AK: MicroRNA
miR-125b controls melanoma progression by direct regulation of c-Jun
protein expression. Oncogene 2013, 32:2984–2991.
20. Shang C, Lu YM, Meng LR: MicroRNA-125b down-regulation mediates
endometrial cancer invasion by targeting ERBB2. Med Sci Monit 2012,
18:BR149–BR155.
21. Henson BJ, Bhattacharjee S, O’Dee DM, Feingold E, Gollin SM: Decreased
expression of miR-125b and miR-100 in oral cancer cells contributes to
malignancy. Genes Chromosomes Cancer 2009, 48:569–582.
22. Liu LH, Li H, Li JP, Zhong H, Zhang HC, Chen J, Xiao T: miR-125b
suppresses the proliferation and migration of osteosarcoma cells
through down-regulation of STAT3. Biochem Biophys Res Commun 2011,
416:31–38.
23. He J, Xu Q, Jing Y, Agani F, Qian X, Carpenter R, Li Q, Wang XR, Peiper SS,
Lu Z, Liu LZ, Jiang BH: Reactive oxygen species regulate ERBB2 and
ERBB3 expression via miR-199a/125b and DNA methylation. EMBO Rep
2012, 13:1116–1122.
24. Zhang Y, Yan LX, Wu QN, Du ZM, Chen J, Liao DZ, Huang MY, Hou JH,
Wu QL, Zeng MS, Huang WL, Zeng YX, Shao JY: miR-125b is methylated
and functions as a tumor suppressor by regulating the ETS1 proto-
oncogene in human invasive breast cancer. Cancer Res 2011, 71:3552–3562.
25. Bousquet M, Harris M, Zhou B, Lodish H: MicroRNA miR-125b causes
leukemia. Proc Natl Acad Sci 2010, 107:21558–21563.
26. Willimott S, Wagner SD: miR-125b and miR-155 contribute to BCL2 repression
and proliferation in response to CD40 ligand (CD154) in human leukemic
B-cells. J Biol Chem 2012, 287:2608–2617.
27. Lin KY, Zhang XJ, Feng DD, Zhang H, Zeng CW, Han BW, Zhou AD, Qu LH,
Xu L, Chen YQ: miR-125b, a target of CDX2, regulates cell differentiation
through repression of the core binding factor in hematopoietic
malignancies. J Biol Chem 2011, 286:38253–38263.
28. Li X, Zhang Y, Zhang H, Liu X, Gong T, Li M, Sun L, Ji G, Shi Y, Han Z, Han S,
Nie Y, Chen X, Zhao Q, Ding J, Wu K, Daiming F: miRNA-223 promotes
gastric cancer invasion and metastasis by targeting tumor suppressor
EPB41L3. Mol Cancer Res 2011, 9:824–833.
29. Vriens MR, Weng J, Suh I, Huynh N, Guerrero MA, Shen WT, Duh QY, Clark
OH, Kebebew E: MicroRNA expression profiling is a potential diagnostic
tool for thyroid cancer. Cancer 2012, 118:3426–3432.
30. Bloomston M, Frankel WL, Petrocca F, Volinia S, Alder H, Hagan JP, Liu CG,
Bhatt D, Taccioli C, Croce CM: MIcrorna expression patterns to
differentiate pancreatic adenocarcinoma from normal pancreas and
chronic pancreatitis. JAMA 2007, 297:1901–1908.
Banzhaf-Strathmann and Edbauer Cell Communication and Signaling 2014, 12:30 Page 12 of 13
http://www.biosignaling.com/content/12/1/3031. Xia HF, He TZ, Liu CM, Cui Y, Song PP, Jin XH, Ma X: MiR-125b expression
affects the proliferation and apoptosis of human glioma cells by
targeting Bmf. Cell Physiol Biochem 2009, 23:347–358.
32. Le MT, Teh C, Shyh-Chang N, Xie H, Zhou B, Korzh V, Lodish HF, Lim B:
MicroRNA-125b is a novel negative regulator of p53. Genes Dev 2009,
23:862–876.
33. Calin GA, Croce CM: MicroRNA signatures in human cancers. Nat Rev
Cancer 2006, 6:857–866.
34. Bousquet M, Quelen C, Rosati R, Mansat-De Mas V, La Starza R, Bastard C,
Lippert E, Talmant P, Lafage-Pochitaloff M, Leroux D, Gervais C, Viguié F,
Lai JL, Terre C, Beverlo B, Sambani C, Hagemeijer A, Marynen P, Delsol G,
Dastugue N, Mecucci C, Brousset P: Myeloid cell differentiation arrest
by miR-125b-1 in myelodysplastic syndrome and acute myeloid
leukemia with the t (2;11) (p21; q23) translocation. J Exp Med 2008,
205:2499–2506.
35. Sonoki T, Iwanaga E, Mitsuya H, Asou N: Insertion of microRNA-125b-1,
a human homologue of lin-4, into a rearranged immunoglobulin heavy
chain gene locus in a patient with precursor B-cell acute lymphoblastic
leukemia. Leukemia 2005, 19:2009–2010.
36. Lee YS, Kim HK, Chung S, Kim K-S, Dutta A: Depletion of Human Micro-RNA
miR-125b Reveals That It Is Critical for the Proliferation of Differentiated
Cells but Not for the Down-regulation of Putative Targets during
Differentiation. J Biol Chem 2005, 280:16635–16641.
37. Le MT, Shyh-Chang N, Khaw SL, Chin L, Teh C, Tay J, O'Day E, Korzh V, Yang H,
Lal A, Lieberman J, Lodish HF, Lim B: Conserved Regulation of p53 Network
Dosage by MicroRNA–125b Occurs through Evolving miRNA–Target Gene
Pairs. PLoS Genet 2011, 7:e1002242.
38. Nishida N, Yokobori T, Mimori K, Sudo T, Tanaka F, Shibata K, Ishii H, Doki Y,
Kuwano H, Mori M: MicroRNA miR-125b is a prognostic marker in human
colorectal cancer. Int J Oncol 2011, 38:1437–1443.
39. Fridman JS, Lowe SW: Control of apoptosis by p53. Oncogene 2003,
22:9030–9040.
40. Scott GK, Goga A, Bhaumik D, Berger CE, Sullivan CS, Benz CC: Coordinate
Suppression of ERBB2 and ERBB3 by Enforced Expression of Micro-RNA
miR-125a or miR-125b. J Biol Chem 2007, 282:1479–1486.
41. Yarden Y: Biology of HER2 and its importance in breast cancer. Oncology 2001,
61(Suppl 2):1–13.
42. Tan M, Yu D: Molecular mechanisms of erbB2-mediated breast cancer
chemoresistance. Adv Exp Med Biol 2007, 608:119–129.
43. Enomoto Y, Kitaura J, Hatakeyama K, Watanuki J, Akasaka T, Kato N,
Shimanuki M, Nishimura K, Takahashi M, Taniwaki M, Haferlach C, Siebert R,
Dyer MJ, Asou N, Aburatani H, Nakakuma H, Kitamura T, Sonoki T: Emu/miR-
125b transgenic mice develop lethal B-cell malignancies. Leukemia 2011,
25:1849–1856.
44. Yuxia M, Zhennan T, Wei Z: Circulating miR-125b is a novel biomarker
for screening non-small-cell lung cancer and predicts poor prognosis.
J Cancer Res Clin Oncol 2012, 138:2045–2050.
45. Chapiro E, Russell LJ, Struski S, Cave H, Radford-Weiss I, Valle VD, Lachenaud
J, Brousset P, Bernard OA, Harrison CJ, Nguyen-Khac F: A new recurrent
translocation t (11;14) (q24; q32) involving IGH@ and miR-125b-1 in
B-cell progenitor acute lymphoblastic leukemia. Leukemia 2010,
24:1362–1364.
46. O’Connell RM, Chaudhuri AA, Rao DS, Gibson WS, Balazs AB, Baltimore D:
MicroRNAs enriched in hematopoietic stem cells differentially regulate
long-term hematopoietic output. Proc Natl Acad Sci U S A 2010,
107:14235–14240.
47. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO: Exosome-
mediated transfer of mRNAs and microRNAs is a novel mechanism of
genetic exchange between cells. Nat Cell Biol 2007, 9:654–659.
48. E-h C, Li H-J, Hua F, Wang B, Mao W, Feng X-R, Li J-Y, Wang X: Serum
microRNA 125b as a diagnostic or prognostic biomarker for advanced
NSCLC patients receiving cisplatin-based chemotherapy. Acta Pharmacol
Sin 2013, 34:309–313.
49. Huang L, Luo J, Cai Q, Pan Q, Zeng H, Guo Z, Dong W, Huang J, Lin T:
MicroRNA-125b suppresses the development of bladder cancer by
targeting E2F3. Int J Cancer 2011, 128:1758–1769.
50. Wu D, Ding J, Wang L, Pan H, Zhou Z, Zhou J, Qu P: microRNA-125b
inhibits cell migration and invasion by targeting matrix
metallopeptidase 13 in bladder cancer. Oncol Lett 2013, 5:829–834.
51. Lin T, Dong W, Huang J, Pan Q, Fan X, Zhang C, Huang L: MicroRNA-143 as
a Tumor Suppressor for Bladder Cancer. J Urol 2009, 181:1372–1380.52. Ferracin M, Bassi C, Pedriali M, Pagotto S, D'Abundo L, Zagatti B, Corrà F,
Musa G, Callegari E, Lupini L, Volpato S, Querzoli P, Negrini M: miR-125b
targets erythropoietin and its receptor and their expression correlates
with metastatic potential and ERBB2/HER2 expression. Mol Cancer 2013,
12:130.
53. Feliciano A, Castellvi J, Artero-Castro A, Leal JA, Romagosa C, Hernández-
Losa J, Peg V, Fabra A, Vidal F, Kondoh H, Ramón Y Cajal S, Lleonart ME:
miR-125b Acts as a Tumor Suppressor in Breast Tumorigenesis via Its
Novel Direct Targets ENPEP, CK2-alpha, CCNJ, and MEGF9. PLoS One
2013, 8:e76247.
54. Rajabi H, Jin C, Ahmad R, McClary C, Joshi MD, Kufe D: MUCIN 1
ONCOPROTEIN EXPRESSION IS SUPPRESSED BY THE miR-125b ONCOMIR.
Genes Cancer 2010, 1:62–68.
55. McKinsey EL, Parrish JK, Irwin AE, Niemeyer BF, Kern HB, Birks DK, Jedlicka P:
A novel oncogenic mechanism in Ewing sarcoma involving IGF
pathway targeting by EWS/Fli1-regulated microRNAs. Oncogene 2011,
30:4910–4920.
56. Li J, You T, Jing J: MiR-125b inhibits cell biological progression of Ewing’s
sarcoma by suppressing the PI3K/Akt signalling pathway. Cell Prolif 2014,
47:152–160.
57. Gong J, Zhang JP, Li B, Zeng C, You K, Chen MX, Yuan Y, Zhuang SM:
MicroRNA-125b promotes apoptosis by regulating the expression of
Mcl-1, Bcl-w and IL-6R. Oncogene 2013, 32:3071–3079.
58. Jia HY, Wang YX, Yan WT, Li HY, Tian YZ, Wang SM, Zhao HL: MicroRNA-
125b Functions as a Tumor Suppressor in Hepatocellular Carcinoma
Cells. Int J Mol Sci 2012, 13:8762–8774.
59. Zhao A, Zeng Q, Xie X, Zhou J, Yue W, Li Y, Pei X: MicroRNA-125b induces
cancer cell apoptosis through suppression of Bcl-2 expression. J Genet
Genomics 2012, 39:29–35.
60. Alpini G, Glaser SS, Zhang JP, Francis H, Han Y, Gong J, Stokes A, Francis T,
Hughart N, Hubble L, Zhuang SM, Meng F: Regulation of placenta growth
factor by microRNA-125b in hepatocellular cancer. J Hepatol 2011,
55:1339–1345.
61. Liang L, Wong CM, Ying Q, Fan DN, Huang S, Ding J, Yao J, Yan M, Li J, Yao
M, Ng IO, He X: MicroRNA-125b suppressesed human liver cancer cell
proliferation and metastasis by directly targeting oncogene LIN28B2.
Hepatology 2010, 52:1731–1740.
62. Li W, Xie L, He X, Li J, Tu K, Wei L, Wu J, Guo Y, Ma X, Zhang P, Pan Z, Hu X,
Zhao Y, Xie H, Jiang G, Chen T, Wang J, Zheng S, Cheng J, Wan D, Yang S,
Li Y, Gu J: Diagnostic and prognostic implications of microRNAs in
human hepatocellular carcinoma. Int J Cancer 2008, 123:1616–1622.
63. Guan Y, Yao H, Zheng Z, Qiu G, Sun K: MiR-125b targets BCL3 and
suppresses ovarian cancer proliferation. Int J Cancer 2011, 128:2274–2283.
64. He J, Jing Y, Li W, Qian X, Xu Q, Li F-S, Liu L-Z, Jiang B-H, Jiang Y: Roles and
Mechanism of miR-199a and miR-125b in Tumor Angiogenesis. PLoS One
2013, 8:e56647.
65. Jin Z, Xu S, Yu H, Yang B, Zhao H, Zhao G: miR-125b inhibits Connexin43
and promotes glioma growth. Cell Mol Neurobiol 2013, 33:1143–1148.
66. Shi L, Zhang J, Pan T, Zhou J, Gong W, Liu N, Fu Z, You Y: MiR-125b is
critical for the suppression of human U251 glioma stem cell
proliferation. Brain Res 2010, 1312:120–126.
67. Shi XB, Xue L, Yang J, Ma AH, Zhao J, Xu M, Tepper CG, Evans CP, Kung HJ,
DeVere White RW: An androgen-regulated miRNA suppresses Bak1
expression and induces androgen-independent growth of prostate
cancer cells. Proc Natl Acad Sci U S A 2007, 104:19983–19988.
68. Amir S, Ma AH, Shi XB, Xue L, Kung HJ, Devere White RW: Oncomir miR-125b
suppresses p14 (ARF) to modulate p53-dependent and p53-independent
apoptosis in prostate cancer. PLoS One 2013, 8:e61064.
69. Sun D, Layer R, Mueller AC, Cichewicz MA, Negishi M, Paschal BM, Dutta A:
Regulation of several androgen-induced genes through the repression
of the miR-99a/let-7c/miR-125b-2 miRNA cluster in prostate cancer cells.
Oncogene 2013, 33:1448–1457.
70. Ozen M, Creighton CJ, Ozdemir M, Ittmann M: Widespread deregulation of
microRNA expression in human prostate cancer. Oncogene 2008,
27:1788–1793.
71. Le MTN, Xie H, Zhou B, Chia PH, Rizk P, Um M, Udolph G, Yang H,
Lim B, Lodish HF: MicroRNA-125b Promotes Neuronal Differentiation
in Human Cells by Repressing Multiple Targets. Mol Cell Biol 2009,
29:5290–5305.
72. Sin WC, Crespin S, Mesnil M: Opposing roles of connexin43 in glioma
progression. Biochim Biophys Acta 2012, 1818:2058–2067.
Banzhaf-Strathmann and Edbauer Cell Communication and Signaling 2014, 12:30 Page 13 of 13
http://www.biosignaling.com/content/12/1/3073. Sen A, Prizant H, Light A, Biswas A, Hayes E, Lee HJ, Barad D, Gleicher N,
Hammes SR: Androgens regulate ovarian follicular development by
increasing follicle stimulating hormone receptor and microRNA-125b
expression. Proc Natl Acad Sci U S A 2014, 111:308–313.
74. Hanahan D, Weinberg Robert A: Hallmarks of Cancer: The Next
Generation. Cell 2011, 144:646–674.
75. Gasco M, Shami S, Crook T: The p53 pathway in breast cancer. Breast Cancer
Res 2002, 4:70–76.
76. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human
cancers. Science 1991, 253:49–53.
77. Inui M, Martello G, Piccolo S: MicroRNA control of signal transduction.
Nat Rev Mol Cell Biol 2010, 11:252–263.
78. Esteller M: Epigenetic gene silencing in cancer: the DNA
hypermethylome. Hum Mol Genet 2007, 16:R50–R59.
79. Schwamborn JC, Berezikov E, Knoblich JA: The TRIM-NHL Protein TRIM32
Activates MicroRNAs and Prevents Self-Renewal in Mouse Neural Progenitors.
Cell 2009, 136:913–925.
80. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100:57–70.
81. Nambiar M, Kari V, Raghavan SC: Chromosomal translocations in cancer.
Biochim Biophys Acta 2008, 1786:139–152.
82. Tindall D, Lonergan P: Androgen receptor signaling in prostate cancer
development and progression. J Carcinog 2011, 10:20.
83. Richmond A, Su Y: Mouse xenograft models vs GEM models for human
cancer therapeutics. Dis Model Mech 2008, 1:78–82.
84. Broderick JA, Zamore PD: MicroRNA therapeutics. Gene Ther 2011,
18:1104–1110.
doi:10.1186/1478-811X-12-30
Cite this article as: Banzhaf-Strathmann and Edbauer: Good guy or bad
guy: the opposing roles of microRNA 125b in cancer. Cell Communication
and Signaling 2014 12:30.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
